川崎病又称黏膜皮肤淋巴结综合征，是小儿后天获得性心脏病的重要病因之一，静脉丙球治疗川崎病防止冠状动脉病变已得到肯定，但如何应用静脉丙球，既安全经济又要有效，一直是儿科探讨的问题。
论著
静脉丙种球蛋白治疗川崎病疗效观察
吴永忠 李肽芝
【摘要】 目的 探讨不同用法静脉输注丙种球蛋白（IVIG）治疗小儿川崎病的临床疗效。方法 对298例川崎病（KD）患儿采用3种不同治疗方案：A组为IVIG 1g/kg单次静脉输注；B组为IVIG 2.0g/kg单次静脉输注，C组为IVIG 0.4g/（kg•d）， 连用4～5d，对比3组治疗后冠状动脉病变(CAD)发生率和急性期临床症状消失时间。
【关键字】 黏膜皮肤淋巴结综合征,免疫球蛋白类,冠状动脉病变
中图分类号：R725.4文献标识码：B文章编号：1671-8194（2011）01-0035-02
Analysis of Treating Kawasaki Disease with Intravenous Immunoglobulin
WU Yong-zhong, LI Tai-zhi
Department of Pediatrics, Taojiang People's Hospital, Taojiang 413400, China
[Abstract] Objective To explore the clinical effect of treating Kawasaki disease with different IVIG dosage. Method 298 patients were divided into 3 groups with different dosage for the treatment: the dosage of Group A was IVIG 1g/kg only once, the dosage of Group B was IVIG 0.4g/（kg·d） everyday, lasting 4～5 days. the dosage of Group C was IVIG 2.0g/（kg·d） only once. Result CAD was effectively prevented by either 1g/kg or only 2.0g/kg or 0.4g/（kg·d）(lasting 4～5 days) of IVIG within 10 days after the onset of the illness. On the remission of acute phrase symptoms, the regimen of 1g/kg or 2.0g/kg IVIG was obviously better than the one of 0.4g/ （kg·d） IVIG, But the group of A and C was not obviously better . Conclusion 1g/kg IVIG is an effective and economic dosage for the treatment of Kawasaki disease.